Table 3.
Univariate and Multivariate Predictors of Progression-Free Survival and Overall Survival After PSM
| Variables | Progression-Free Survival | Overall Survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||||||
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age (years) | ||||||||||||
| ≤50/>50 | 0.306 | 0.148–0.631 | 0.001 | 0.260 | 0.112–0.605 | 0.002 | 0.653 | 0.297–1.438 | 0.290 | |||
| Sex | ||||||||||||
| Male/Female | 1.803 | 0.735–4.420 | 0.198 | 2.571 | 0.995–6.644 | 0.051 | ||||||
| ECOG PS | ||||||||||||
| 0/1 | 1.439 | 0.681–3.041 | 0.340 | 2.251 | 0.944–5.371 | 0.067 | ||||||
| Child-Pugh class | ||||||||||||
| A5/A6+B7 | 2.660 | 1.276–5.545 | 0.009 | 3.125 | 1.293–7.555 | 0.011 | 1.722 | 0.809–3.655 | 0.159 | |||
| AFP (ng/mL) | ||||||||||||
| ≤400/>400 | 1.545 | 0.766–3.115 | 0.224 | 2.980 | 1.399–6.346 | 0.005 | 2.625 | 1.194–5.770 | 0.016 | |||
| HBsAg | ||||||||||||
| Positive/negative | 1.780 | 0.774–4.093 | 0.175 | 1.574 | 0.626–3.958 | 0.335 | ||||||
| NLR | ||||||||||||
| Low/high | 1.318 | 0.662–2.627 | 0.432 | 1.283 | 0.598–2.753 | 0.522 | ||||||
| PLR | ||||||||||||
| Low/high | 1.445 | 0.714–2.926 | 0.308 | 2.291 | 1.071–4.899 | 0.033 | 2.384 | 1.006–5.648 | 0.048 | |||
| AST (U/L) | ||||||||||||
| ≤40/>40 | 1.324 | 0.634–2.764 | 0.455 | 1.410 | 0.618–3.213 | 0.414 | ||||||
| ALT (U/L) | ||||||||||||
| ≤35/>35 | 0.561 | 0.274–1.152 | 0.115 | 0.404 | 0.185–0.884 | 0.023 | 0.405 | 0.176–0.932 | 0.034 | |||
| Albumin level (g/L) | ||||||||||||
| ≤35/>35 | 0.567 | 0.273–1.180 | 0.129 | 0.676 | 0.315–1.449 | 0.314 | ||||||
| BCLC stage | ||||||||||||
| B/C | 1.825 | 0.844–3.946 | 0.127 | 1.353 | 0.573–3.197 | 0.490 | ||||||
| Tumor number | ||||||||||||
| ≤3/>3 | 1.521 | 0.709–3.267 | 0.282 | 1.295 | 0.585–2.864 | 0.524 | ||||||
| Tumor size (cm) | ||||||||||||
| ≤5/>5 | 0.962 | 0.483–1.918 | 0.913 | 1.055 | 0.477–2.335 | 0.894 | ||||||
| Vascular invasion | ||||||||||||
| Yes/No | 1.039 | 0.550–1.960 | 0.907 | 0.886 | 0.431–1.822 | 0.742 | ||||||
| Extrahepatic metastasis | ||||||||||||
| Yes/No | 0.544 | 0.272–1.088 | 0.085 | 0.838 | 0.397–1.767 | 0.642 | ||||||
| First-line treatment | ||||||||||||
| Lenvatinib/sorafenib | 1.048 | 0.491–2.238 | 0.903 | 1.921 | 0.657–5.620 | 0.233 | ||||||
| ICIs treatment | ||||||||||||
| Camrelizumab/sintilimab | 1.179 | 0.590–2.358 | 0.641 | 1.084 | 0.506–2.322 | 1.084 | ||||||
| Treatment | ||||||||||||
| R+ICIs/R+ICIs+TACE | 0.213 | 0.089–0.508 | <0.001 | 0.244 | 0.096–0.622 | 0.003 | 0.385 | 0.175–0.850 | 0.018 | 0.410 | 0.170–0.988 | 0.047 |
Notes: Analyses were performed using Cox proportional hazard regression model.
Abbreviations: HR, Hazard Ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; AFP, α-fetoprotein; HBsAg, hepatitis B surface antigen; NLR, Neutrophil-to-lymphocyte ratio; NLR low, NLR ≤ 4; NLR high, NLR > 4; PLR, platelet-to-lymphocyte ratio; PLR low, PLR ≤ 133; PLR high, PLR > 133; AST, aspartate transaminase; ALT, alanine transaminase; BCLC, Barcelona Clinic Liver Cancer; PR, partial response; SD, stable disease; PD, progressive disease; ICIs, Immune Checkpoint Inhibitors; R+ICIs, regorafenib+immune checkpoint inhibitors; R+ICIs+TACE, regorafenib+immune checkpoint inhibitors+transarterial chemoembolization.